Myeloma New Zealand has made a submission on the Therapeutic Products Bill, as it has implications for Myeloma Patients. The Chair of the Health Committee has called for public submissions on the Therapeutic Products Bill. Therapeutic Products are medicines, medical devices, natural health products, and pharmaceutical ingredients. The bill seeks to provide for the regulation...Continue Reading
Nathaniel works in the research team, where the CAR T-cells are designed, and supports both the GMP team, where the CAR T-cells are manufactured, and the clinical team, who administer the CAR T-cells to participants in the trial. Read more here: First-car-t-cell-therapy-clinical-trialContinue Reading
MEDIA RELEASE 7 September 2022 New Zealanders living with multiple myeloma, a deadly, relapsing/remitting blood cancer, are mounting a major, evidence-based campaign to press Pharmac into funding a transformative treatment that has been standard-of-care throughout the OECD for more than 5 years. Myeloma patient and trustee of Myeloma NZ Nichola Oakenfull says patients who’ve...Continue Reading
OPINION: How long does it take you to make a decision about whether or not to buy something? You’ve got all the information in front of you. You know it’s a good product. It works. You need it. And you’ve got the money to buy it. So how long will it take? What if I said...Continue Reading
In August 2022, Myeloma New Zealand is hosting its 4th Myeloma Summit for medical professionals in Queenstown. Held in 2016,2018, 2020 and now again in 2022, the Summit brings together medical professionals involved with Myeloma in NZ to share and to learn from one another and from the international speakers who join the meeting. This year...Continue Reading
MEDIA RELEASE DOCTOR CALLS ON MINISTER LITTLE TO RELEASE ‘BURIED’ INDEPENDENT REPORT ON PHARMAC The final report of the Independent Pharmac Review Panel has been sitting with Health Minister Andrew Little since February, with no reason offered for why it has not been released, says Myeloma NZ Chief Executive Dr Ken Romeril. “Given the damning...Continue Reading
